东诚药业(002675.SZ):鲁鼎思诚拟6个月内减持不超1.75%股份
格隆汇8月27日丨东诚药业(002675.SZ)公布,公司于2019年8月27日收到持股2.18%的股东鲁鼎思诚出具的《股份减持计划告知函》。鲁鼎思诚拟自公告之日起6个月内通过集中竞价和大宗交易方式减持公司股份不超过1400.2332万股,即不超过公司总股本的1.75%。
其中,通过集中竞价交易方式减持的,在减持公告披露15个交易日后开始减持,任意连续90个自然日内不超过公司股份总数的1%;通过大宗交易方式减持的,在减持公告披露3个交易日后开始减持,任意连续90个自然日内不超过公司股份总数的2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.